{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:58Z","timestamp":1786979938263,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune thrombocytopenia (ITP) is an immune-mediated disease that results in low platelet counts. Despite appropriate treatment, many patients continue to experience refractory disease. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, has emerged as a promising option for refractory ITP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This meta-analysis aims to evaluate the efficacy and safety of fostamatinib compared to conventional therapy in adults aged\u2009\u2265\u200918 years with refractory ITP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Literature search was conducted in PubMed, Scopus, Embase, and clinicaltrials.gov databases from inception to March 31, 2024. Randomized controlled trials (RCTs) assessing the safety and efficacy of fostamatinib in adults with refractory ITP were included. Data extraction, risk of bias assessment, and statistical analysis were performed following PRISMA guideline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 495 articles were screened, with three RCTs meeting the inclusion criteria. Fostamatinib therapy demonstrated superior efficacy in achieving stable platelet response by week 24 (ORR 0.80; 95%CI 0.72\u20130.88), platelet count\u2009\u2265\u200950,000\/\u00b5L at weeks 12 (ORR 0.80; 95%CI 0.72\u20130.90) and week 24 (ORR 0.82; 95%CI 0.72\u20130.90). Additionally, fostamatinib improves platelet counts in subjects with a baseline count of &lt;\u200915,000\/\u00b5L. The Number Needed to Treat (NNT) was calculated as 10. Adverse effects include diarrhea (RR 2.32; 95%CI 1.11\u20134.84), hypertension (RR 2.33; 95%CI 1.00-5.43), and abnormal liver function tests (RR 4.18; 95% CI 1.00-17.48). Interestingly, the occurrences of nausea (RR 1.77; 95% CI 0.33\u20139.67) and rash (RR 2.28; 95% CI\u00a00.50-10.29) did not achieve statistical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis provides robust evidence supporting the efficacy of fostamatinib in improving platelet counts and achieving therapeutic goals in adults with refractory ITP. However, fostamatinib\u2019s safety profile warrants consideration due to higher rates of diarrhea, hypertension, and abnormal liver function tests.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00277-024-05824-7","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:02:00Z","timestamp":1717977720000},"page":"3357-3368","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9910-6563","authenticated-orcid":false,"given":"Songphol","family":"Tungjitviboonkun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4753-7318","authenticated-orcid":false,"given":"Naharuthai","family":"Bumrungratanayos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedsadakorn","family":"Jitwimungsanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanat","family":"Kheamakulvanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smuch","family":"Siramongkholkarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"issue":"11","key":"5824_CR1","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386\u20132393. https:\/\/doi.org\/10.1182\/blood-2008-07-162503","journal-title":"Blood"},{"issue":"3","key":"5824_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ajh.21616","volume":"85","author":"DR Terrell","year":"2010","unstructured":"Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN (2010) The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 85(3):174\u2013180. https:\/\/doi.org\/10.1002\/ajh.21616","journal-title":"Am J Hematol"},{"issue":"23","key":"5824_CR3","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM et al (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3(23):3829\u20133866. https:\/\/doi.org\/10.1182\/bloodadvances.2019000966","journal-title":"Blood Adv"},{"issue":"1","key":"5824_CR4","doi-asserted-by":"publisher","first-page":"2131751","DOI":"10.1080\/09537104.2022.2131751","volume":"34","author":"N Cooper","year":"2023","unstructured":"Cooper N, Ghanima W, Hill QA, Nicolson PL, Markovtsov V, Kessler C (2023) Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib. Platelets 34(1):2131751. https:\/\/doi.org\/10.1080\/09537104.2022.2131751","journal-title":"Platelets"},{"issue":"11","key":"5824_CR5","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1002\/art.23992","volume":"58","author":"ME Weinblatt","year":"2008","unstructured":"Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al (2008) Treatment of rheumatoid arthritis with a syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 58(11):3309\u20133318. https:\/\/doi.org\/10.1002\/art.23992","journal-title":"Arthritis Rheum"},{"issue":"14","key":"5824_CR6","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","volume":"363","author":"ME Weinblatt","year":"2010","unstructured":"Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB (2010) An oral spleen tyrosine kinase (syk) inhibitor for rheumatoid arthritis. N Engl J Med 363(14):1303\u20131312. https:\/\/doi.org\/10.1056\/NEJMoa1000500","journal-title":"N Engl J Med"},{"issue":"3","key":"5824_CR7","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1124\/jpet.106.109058","volume":"319","author":"S Braselmann","year":"2006","unstructured":"Braselmann S, Taylor V, Zhao H et al (2006) R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319(3):998\u20131008. https:\/\/doi.org\/10.1124\/jpet.106.109058","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"5824_CR8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40262-022-01135-0","volume":"61","author":"R Matsukane","year":"2022","unstructured":"Matsukane R, Suetsugu K, Hirota T, Ieiri I (2022) Clinical pharmacokinetics and Pharmacodynamics of Fostamatinib and its active Moiety R406. Clin Pharmacokinet 61(7):955\u2013972. https:\/\/doi.org\/10.1007\/s40262-022-01135-0","journal-title":"Clin Pharmacokinet"},{"key":"5824_CR9","first-page":"537","volume":"17","author":"KH Kirin","year":"2018","unstructured":"Kirin KH (2018) mAb X-linked F. FDA new drug approvals in Q2 2018. Nat Reviews| Drug Discovery 17:537","journal-title":"Nat REVIEWS| DRUG DISCOVERY"},{"issue":"5","key":"5824_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ajh.25444","volume":"94","author":"JB Bussel","year":"2019","unstructured":"Bussel JB, Arnold DM, Boxer MA et al (2019) Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol 94(5):546\u2013553. https:\/\/doi.org\/10.1002\/ajh.25444","journal-title":"Am J Hematol"},{"issue":"6","key":"5824_CR11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/bjh.18582","volume":"200","author":"M Kuwana","year":"2023","unstructured":"Kuwana M, Ito T, Kowata S et al (2023) Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: a phase 3, placebo-controlled, double-blind, parallel-group study. Br J Haematol 200(6):802\u2013811. https:\/\/doi.org\/10.1111\/bjh.18582","journal-title":"Br J Haematol"},{"key":"5824_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"5824_CR13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"1","key":"5824_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1080\/16078454.2019.1568659","volume":"24","author":"R Yang","year":"2019","unstructured":"Yang R, Lin L, Yao H, Ji O, Shen Q (2019) Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis. Hematology 24(1):290\u2013299. https:\/\/doi.org\/10.1080\/16078454.2019.1568659","journal-title":"Hematology"},{"issue":"12","key":"5824_CR15","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s00277-021-04669-8","volume":"100","author":"I Cohen","year":"2021","unstructured":"Cohen I, Goldvaser H, Kirgner I et al (2021) Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. Ann Hematol 100(12):2879\u20132887. https:\/\/doi.org\/10.1007\/s00277-021-04669-8","journal-title":"Ann Hematol"},{"issue":"1","key":"5824_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/1573396315666191023122542","volume":"16","author":"DO Acero-Garces","year":"2020","unstructured":"Acero-Garces DO, Garcia-Perdomo HA (2020) First Line treatments for newly diagnosed primary Immune Thrombocytopenia in children: a systematic review and network Meta-analysis. Curr Pediatr Rev 16(1):61\u201370. https:\/\/doi.org\/10.2174\/1573396315666191023122542","journal-title":"Curr Pediatr Rev"},{"issue":"1","key":"5824_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3324\/haematol.2017.174615","volume":"103","author":"Y Arai","year":"2018","unstructured":"Arai Y, Jo T, Matsui H, Kondo T, Takaori-Kondo A (2018) Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis. Haematologica 103(1):163\u2013171. https:\/\/doi.org\/10.3324\/haematol.2017.174615","journal-title":"Haematologica"},{"key":"5824_CR18","doi-asserted-by":"publisher","first-page":"101777","DOI":"10.1016\/j.eclinm.2022.101777","volume":"56","author":"Y Wang","year":"2023","unstructured":"Wang Y, Sheng L, Han F et al (2023) Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: a systematic review and network meta-analysis. EClinicalMedicine 56:101777. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101777","journal-title":"EClinicalMedicine"},{"issue":"8","key":"5824_CR19","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1080\/09537104.2018.1543864","volume":"30","author":"Y Arai","year":"2019","unstructured":"Arai Y, Matsui H, Jo T, Kondo T, Takaori-Kondo A (2019) Comparison of treatments for persistent\/chronic immune thrombocytopenia: a systematic review and network meta-analysis. Platelets 30(8):946\u2013956. https:\/\/doi.org\/10.1080\/09537104.2018.1543864","journal-title":"Platelets"},{"issue":"3","key":"5824_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjh.16161","volume":"188","author":"T Puavilai","year":"2020","unstructured":"Puavilai T, Thadanipon K, Rattanasiri S et al (2020) Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis. Br J Haematol 188(3):450\u2013459. https:\/\/doi.org\/10.1111\/bjh.16161","journal-title":"Br J Haematol"},{"issue":"6","key":"5824_CR21","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1007\/s12325-021-01752-4","volume":"38","author":"P Wojciechowski","year":"2021","unstructured":"Wojciechowski P, Wilson K, Nazir J et al (2021) Efficacy and safety of Avatrombopag in patients with chronic Immune Thrombocytopenia: a systematic literature review and network Meta-analysis. Adv Ther 38(6):3113\u20133128. https:\/\/doi.org\/10.1007\/s12325-021-01752-4","journal-title":"Adv Ther"},{"issue":"3","key":"5824_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000528642","volume":"146","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhang HX, Su J, Geng QC, Lin X, Feng CX (2023) Efficacy and incidence of treatment-related adverse events of Thrombopoietin receptor agonists in adults with Immune Thrombocytopenia: a systematic review and network Meta-analysis of Randomized Controlled Study. Acta Haematol 146(3):173\u2013184. https:\/\/doi.org\/10.1159\/000528642","journal-title":"Acta Haematol"},{"issue":"6","key":"5824_CR23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14656566.2023.2198089","volume":"24","author":"T Li","year":"2023","unstructured":"Li T, Liu Q, Pu T, Liu J, Zhang A (2023) Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis. Expert Opin Pharmacother 24(6):763\u2013774. https:\/\/doi.org\/10.1080\/14656566.2023.2198089","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"5824_CR24","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00277-022-04784-0","volume":"101","author":"H Zhou","year":"2022","unstructured":"Zhou H, Fan J, He J, Hu S (2022) Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: a multiple-treatments network meta-analysis. Ann Hematol 101(5):953\u2013961. https:\/\/doi.org\/10.1007\/s00277-022-04784-0","journal-title":"Ann Hematol"},{"issue":"6","key":"5824_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/bjh.16959","volume":"190","author":"R Boccia","year":"2020","unstructured":"Boccia R, Cooper N, Ghanima W et al (2020) Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. Br J Haematol 190(6):933\u2013938. https:\/\/doi.org\/10.1111\/bjh.16959","journal-title":"Br J Haematol"},{"key":"5824_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19443","author":"R Jimenez-Barcenas","year":"2024","unstructured":"Jimenez-Barcenas R, Garcia-Donas-Gabaldon G, Campos-Alvarez RM et al (2024) Treatment with fostamatinib in patients with immune thrombocytopenia: experience from the andalusian region in Spain-the Fostasur Study. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.19443","journal-title":"Br J Haematol"},{"key":"5824_CR27","doi-asserted-by":"publisher","DOI":"10.1159\/000533175","author":"G Dranitsaris","year":"2023","unstructured":"Dranitsaris G, Peevyhouse A, Wood T, Kreychman Y, Neuhalfen H, Moezi M (2023) Fostamatinib or Thrombopoietic receptor agonists for the treatment of Chronic Immune Thrombocytopenia in Adult patients: a Real-World Assessment of Safety, effectiveness and cost. Acta Haematol. https:\/\/doi.org\/10.1159\/000533175","journal-title":"Acta Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05824-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05824-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05824-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T05:14:03Z","timestamp":1724822043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05824-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["5824"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05824-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"10 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}